Axiom-4 astronauts discuss ‘trust' in NASA amid ISS leak
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
15 minutes ago
- Entrepreneur
Drizz, Hey Concrete, and Genexis Biotech Raise Funding for Growth
The below brands have announced their latest funding rounds. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Drizz Secures USD 2.7 Mn to Advance Vision AI Mobile App Testing Drizz, a vision AI-powered mobile app testing company, has raised 2.7 million dollars in seed funding from Stellaris Venture Partners, with participation from Shastra VC, Anuj Rathi and Vaibhav Domkundwar. The funds will be used to enhance Drizz's Vision AI engine, expand its engineering team and strengthen research capabilities. Founded in 2024 by former Amazon, Coinbase and Gojek engineers Asad Abrar, Partha Sarathi Mohanty and Yash Varyani, Drizz aims to address the challenges of mobile app quality assurance. Its platform replaces traditional locator-based test scripts with natural language prompts, enabling testing across iOS and Android in plain English. The system is designed to deliver over 97 percent test reliability while reducing the time needed for test creation. "Every app team is accelerating with AI, but testing still lags behind," said Asad Abrar, Co-founder and chief executive officer. "We built Drizz to keep up with modern development and deliver confidence at scale." Drizz supports no-code setup, CI/CD integration and multiple forms of testing, including UI, functional, API, multi-app and end-to-end. Its AI evaluates apps visually, adapting automatically to interface changes, screen densities and hardware variations. Alok Goyal, partner at Stellaris Venture Partners, said the company is addressing a key bottleneck in software development by taking a vision-first approach to mobile application testing. Udaipur's Hey Concrete Attracts INR 7.5 Cr to Drive Global Expansion Udaipur-based Hey Concrete has raised INR 7.5 crore in a strategic investment from Kamlesh Arjun Choudhari, a veteran in the global facades and cladding sector. The funding will be directed toward setting up an advanced manufacturing unit, expanding into key international architectural markets, and strengthening outreach for the company's GreenPro-certified concrete solutions. Founded by Aseem Bolia in Udaipur, Hey Concrete specialises in architecturally inspired, eco-conscious concrete products that combine design versatility with performance features such as fire resistance and sustainability. Its portfolio includes claddings, breeze blocks, murals, and other decorative yet functional concrete elements, with over 30 showrooms established across India. "This partnership is deeply personal to us," said Bolia. "Kamlesh's belief in our mission energizes our commitment to making Indian design and sustainability a global benchmark." Choudhari, who has over two decades of industry experience and a presence in markets across North America, the Middle East, and Australia, expressed confidence in the company's direction. "Hey Concrete is reshaping the possibilities of concrete with innovation rooted in function, design, and purpose," he said. Co-founders Shubham Babel and Shabbir H Rahim highlighted that the partnership will accelerate product evolution and global expansion while maintaining a focus on responsible, design-led innovation. With its emphasis on both aesthetics and environmental responsibility, Hey Concrete has contributed to more than 2,500 projects in India and is now positioning its products for broader global adoption, aiming to showcase Indian material innovation on an international stage. Genexis Biotech Secures INR 4 Cr to Expand Recombinant Protein Production Genexis Biotech, a Vadodara-based bio-manufacturing startup, has raised INR 4 crore in a seed funding round from GVFL with additional participation from Benzai10. The startup plans to use the funds to expand its bioreactor capacity, establish downstream processing infrastructure, introduce new recombinant proteins and enzymes, and enhance compliance, sales, and distribution operations. Founded in 2022, Genexis Biotech develops animal-origin-free recombinant proteins through precision fermentation for sectors including biopharma, food technology, and cell culture. Its current facility is a certified Class 10,000 cleanroom, and the company is building a GMP-compliant unit to support future growth. The product line includes recombinant peptidases such as amino peptidase and enterokinase, with upcoming launches of recombinant transferrin and albumin. In the past year, the startup partnered with pharmaceutical and biotech companies, signed an MoU with the Gujarat government, and secured orders for alternative protein formulations. The firm also aims to tap into regulated biotech export markets and explore collaborations with contract development and manufacturing organisations.
Medscape
15 minutes ago
- Medscape
Preterm Birth Predicts Adult Health Problems
Adults born preterm were significantly more likely to have cardiometabolic risk factors and internalized mental health issues than full-term peers, according to an ongoing preterm birth cohort study in the US. 'This study addresses a significant gap in understanding the long-term health effects of preterm birth in the US,' said lead author Amy D'Agata, PhD, of the College of Nursing, The University of Rhode Island, Kingston, Rhode Island, in an interview. Although the annual preterm birth rate in the US has held at a relatively stable 10%-12% for decades, since the 1970s, more preterm infants are surviving because of advances in neonatal intensive care, D'Agata said. Millions of individuals born preterm are aging into adulthood, but few data are available on their long-term health outcomes, she noted. In the new study, published in JAMA Network Open , D'Agata and colleagues reviewed data from a cohort of individuals who received level III neonatal intensive care at a single center between 1985 and 1989. The study population included 158 preterm-born and 55 full-term born adult control individuals. Preterm was defined as weighing under 1850 g at birth with various neonatal diagnoses; critically ill infants and those with major congenital abnormalities were excluded. The mean age across the groups was 35 years; 50% were women. The researchers used latent growth curve models to show changes over time. Overall, the preterm individuals who had higher medical risk in early life were significantly more likely to have a range of health problems at 35 years of age, notably, higher triglycerides than control individuals (beta value, 53.97; P = .03). Measures of systolic blood pressure and central adiposity also were significantly higher in the preterm birth group (beta values of 7.15 and 0.22, respectively), whereas bone density and high-density lipoprotein cholesterol were lower (beta values of -1.14 and -13.07, respectively). In addition, internalizing mental health problems were significantly more common in the preterm cohort than in the control individuals (beta value, 0.85; P = .01) but no difference in externalizing mental health problems was noted between the groups. The researchers also reviewed the impact of social protection and childhood socioeconomic status and found no association between these and physical or psychological health risks in adults born preterm. The Long View of Preterm Birth The population of adults born preterm remains largely invisible to the US healthcare system and its clinicians, highlighting critical issues of health equity and quality of care, D'Agata told Medscape Medical News . 'Much of the existing research in this area has focused on international, homogeneous populations, creating a need for rigorous, US-based longitudinal data to guide healthcare policy and clinical practice,' she added. 'These findings generally confirmed what has been observed internationally, that there is a link between higher early life medical risk and increased likelihood of mental health issues, elevated systolic blood pressure, unfavorable cholesterol and triglyceride levels, body fat distribution, and lower bone density among adults born preterm, and it was notable to see these clear and consistent associations replicated in a US cohort using a prospective, longitudinal design,' said D'Agata. The study findings emphasized the need to inquire about birth history in adult care settings and suggest that those born preterm and their families must be their own health advocates, if necessary, said D'Agata. 'Even if a patient isn't asked about their birth history, they should share it,' she noted. Clinicians work hard to provide the best care, but it takes time for evidence-based research to inform clinical practice, she said. 'Although our birth cohort is small and comes from a single geographic region, the results generally align with international findings,' D'Agata told Medscape Medical News . However, future studies should include more racially and ethnically diverse cohorts from multiple clinical settings, she said. Research is needed not only to examine which subgroups of preterm individuals are most at risk but also to differentiate between those with varying degrees of early life complications, she added. Long Follow-Up Strengthens Findings The 35-year duration of the preterm birth cohort study was impressive and valuable, said Tim Joos, MD, a clinician with a combination internal medicine/pediatrics practice at Neighborcare Health in Seattle. 'We don't often have the long game in mind, in healthcare as well as in other parts of our society,' said Joos, who was not involved in the study. 'We don't tend to follow pediatric conditions into adulthood,' he noted. The current study findings demonstrated a long-term psychological and physical impact of prematurity on adult health that was humbling, Joos told Medscape Medical News . Looking ahead, the results highlight not only the need to continue to prevent preterm birth but also to the importance of asking older patients about preterm birth as part of their health history, he said.
Bloomberg
16 minutes ago
- Bloomberg
Trade Deals Lose Markets Potency as EU Deal Makes Little Splash
Donald Trump may have called it 'the biggest of all the deals,' but the EU-US trade pact failed to boost risk appetite in a sign the incremental impact from each new agreement is fading. Markets around the world posted relatively small moves Monday, with modest losses in European equities and the euro, while US stocks ended flat. By comparison, when the US-Japan trade deal was announced last week, Japanese and US shares both rallied sharply.
